Literature DB >> 8321198

Control of fibroblast growth factor receptor kinase signal transduction by heterodimerization of combinatorial splice variants.

E Shi1, M Kan, J Xu, F Wang, J Hou, W L McKeehan.   

Abstract

A differentiated liver cell (HepG2), which exhibits a dose-dependent growth-stimulatory and growth-inhibitory response to heparin-binding fibroblast growth factor type 1 (FGF-1), displays high- and low-affinity receptor phenotypes and expresses specific combinatorial splice variants alpha 1, beta 1, and alpha 2 of the FGF receptor (FGF-R) gene (flg). The extracellular domains of the alpha and beta variants consist of three and two immunoglobulin loops, respectively, while the intracellular variants consist of a tyrosine kinase (type 1) isoform and a kinase-defective (type 2) isoform. The type 2 isoform is also devoid of the two major intracellular tyrosine autophosphorylation sites (Tyr-653 and Tyr-766) in the type 1 kinase. An analysis of ligand affinity, dimerization, autophosphorylation, and interaction with src homology region 2 (SH2) substrates of the recombinant alpha 1, beta 1, and alpha 2 isoforms was carried out to determine whether dimerization of the combinatorial splice variants might explain the dose-dependent opposite mitogenic effects of FGF. Scatchard analysis indicated that the alpha and beta isoforms exhibit low and high affinity for ligand, respectively. The three combinatorial splice variants dimerized in all combinations. FGF enhanced dimerization and kinase activity, as assessed by receptor autophosphorylation. Phosphopeptide analysis revealed that phosphorylation of Tyr-653 was reduced relative to phosphorylation of Tyr-766 in the type 1 kinase component of heterodimers of the type 1 and type 2 isoforms. The SH2 domain substrate, phospholipase C gamma 1 (PLC gamma 1), associated with the phosphorylated type 1-type 2 heterodimers but was phosphorylated only in preparations containing the type 1 kinase homodimer. The results suggest that phosphorylation of Tyr-653 within the kinase catalytic domain, but not Tyr-766 in the COOH-terminal domain, may be stringently dependent on a trans intermolecular mechanism within FGF-R kinase homodimers. Although phosphotyrosine 766 is sufficient for interaction of PLC gamma 1 and other SH2 substrates with the FGF-R kinase, phosphorylation and presumably activation of substrates require the kinase homodimer and phosphorylation of Tyr-653. We propose that complexes of phosphotyrosine 766 kinase monomers and SH2 domain signal transducers may constitute unactivated presignal complexes whose active or inactive fate depends on homodimerization with a kinase or heterodimerization with a kinase-defective monomer, respectively. The results suggest a mechanism for control of signal transduction by different concentrations of ligand through heterodimerization of combinatorial splice variants from the same receptor gene.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8321198      PMCID: PMC359927          DOI: 10.1128/mcb.13.7.3907-3918.1993

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  45 in total

1.  Expression and transforming activity of a variant of the heparin-binding fibroblast growth factor receptor (flg) gene resulting from splicing of the alpha exon at an alternate 3'-acceptor site.

Authors:  G Yan; F Wang; Y Fukabori; D Sussman; J Hou; W L McKeehan
Journal:  Biochem Biophys Res Commun       Date:  1992-03-16       Impact factor: 3.575

2.  Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation.

Authors:  Y Yarden; J Schlessinger
Journal:  Biochemistry       Date:  1987-03-10       Impact factor: 3.162

3.  A one-step purification of membrane proteins using a high efficiency immunomatrix.

Authors:  C Schneider; R A Newman; D R Sutherland; U Asser; M F Greaves
Journal:  J Biol Chem       Date:  1982-09-25       Impact factor: 5.157

4.  Point mutation of an FGF receptor abolishes phosphatidylinositol turnover and Ca2+ flux but not mitogenesis.

Authors:  K G Peters; J Marie; E Wilson; H E Ives; J Escobedo; M Del Rosario; D Mirda; L T Williams
Journal:  Nature       Date:  1992-08-20       Impact factor: 49.962

5.  Point mutation in FGF receptor eliminates phosphatidylinositol hydrolysis without affecting mitogenesis.

Authors:  M Mohammadi; C A Dionne; W Li; N Li; T Spivak; A M Honegger; M Jaye; J Schlessinger
Journal:  Nature       Date:  1992-08-20       Impact factor: 49.962

6.  Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of 2-deoxyglucose.

Authors:  L Ellis; E Clauser; D O Morgan; M Edery; R A Roth; W J Rutter
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

7.  An essential heparin-binding domain in the fibroblast growth factor receptor kinase.

Authors:  M Kan; F Wang; J Xu; J W Crabb; J Hou; W L McKeehan
Journal:  Science       Date:  1993-03-26       Impact factor: 47.728

8.  Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor.

Authors:  Y Yarden; J Schlessinger
Journal:  Biochemistry       Date:  1987-03-10       Impact factor: 3.162

9.  High and low affinity binding of heparin-binding growth factor to a 130-kDa receptor correlates with stimulation and inhibition of growth of a differentiated human hepatoma cell.

Authors:  M Kan; D DiSorbo; J Z Hou; H Hoshi; P E Mansson; W L McKeehan
Journal:  J Biol Chem       Date:  1988-08-15       Impact factor: 5.157

Review 10.  The steroid and thyroid hormone receptor superfamily.

Authors:  R M Evans
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

View more
  37 in total

Review 1.  Cellular signaling by fibroblast growth factors (FGFs) and their receptors (FGFRs) in male reproduction.

Authors:  Leanne M Cotton; Moira K O'Bryan; Barry T Hinton
Journal:  Endocr Rev       Date:  2008-01-23       Impact factor: 19.871

Review 2.  FGFR3-related dwarfism and cell signaling.

Authors:  Daisuke Harada; Yoshitaka Yamanaka; Koso Ueda; Hiroyuki Tanaka; Yoshiki Seino
Journal:  J Bone Miner Metab       Date:  2008-12-09       Impact factor: 2.626

Review 3.  Growth factors in bladder cancer.

Authors:  M Liebert
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

4.  The alternatively spliced acid box region plays a key role in FGF receptor autoinhibition.

Authors:  Juliya Kalinina; Kaushik Dutta; Dariush Ilghari; Andrew Beenken; Regina Goetz; Anna V Eliseenkova; David Cowburn; Moosa Mohammadi
Journal:  Structure       Date:  2012-01-11       Impact factor: 5.006

5.  Reconstitution of fibroblast growth factor receptor interactions in the yeast two hybrid system.

Authors:  R Aloni-Grinstein; A Seddon; A Yayon
Journal:  Mol Biotechnol       Date:  1999-06       Impact factor: 2.695

6.  Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas.

Authors:  F Yamaguchi; H Saya; J M Bruner; R S Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

Review 7.  Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas.

Authors:  R S Morrison; F Yamaguchi; H Saya; J M Bruner; A M Yahanda; L A Donehower; M Berger
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy.

Authors:  G Yan; Y Fukabori; G McBride; S Nikolaropolous; W L McKeehan
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

Review 9.  Mechanisms of restenosis.

Authors:  W Casscells; D Engler; J T Willerson
Journal:  Tex Heart Inst J       Date:  1994

10.  Reconstitution of a pentameric complex of dimeric transforming growth factor beta ligand and a type I, II, III receptor in baculoviral-infected insect cells.

Authors:  K Matsuzaki; M Kan; W L McKeehan
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-06       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.